Загрузка...
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following molecular profiling has dramatically changed the way advanced adenocarcinoma is treated. However, tumor cells inevitably acquire resistance to such therapies, circumventing any sustained clinical benefit. A...
Сохранить в:
| Опубликовано в: : | J Mol Med (Berl) |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5696571/ https://ncbi.nlm.nih.gov/pubmed/24852181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00109-014-1165-y |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|